French expenditure on reimbursable devices continues double-digit rise
This article was originally published in Clinica
Executive Summary
The amount reimbursed by the French social security for medical products generally intended for direct use by individual patients in 2001 was E2,989bn ($2,800bn) compared with was some E2.7bn in 2000, an increase of 13%. This is an improvement compared with the average rate of some 15% over between 1998 and 2000, but is still much higher than the increase in the overall healthcare expenditure budget, which was set at 3.5% for 2001 and means that it will undoubtedly be targeted for cuts by the new government.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.